Abstract
In the postmenopausal women, adnexal masses can have numerous etiologies. They can range from benign to neoplastic, with origins from a variety of organ systems. The diagnostic work up includes a thorough history, physical exam, as well as potential imaging and laboratory testing. There should be a low threshold for consultations with oncologists when there are cancer concerns. Specifically for gynecologic neoplasms, a referral to a gynecologic oncologist should be strongly considered. In this paper, there is particular attention to ovarian cancer given the gravity of delayed diagnosis.
Keywords: Adnexal mass, postmenopausal, ovarian cancer, ROMA, HE4, CA125, OVA.
Graphical Abstract
[2]
Available from:. https://www.cancer.org/content/dam/cancer-org/ research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/ 2017/cancer-facts-and-figures-2017.pdf (Accessed on: June 3, 2017).
[3]
Herzog TJ. The current treatment of recurrent ovarian cancer. Curr Oncol Rep 2006; 8(6): 448-54.
[4]
U.S. Cancer Statistics Working Group. United States Cancer Statistics:
1999–2014 Incidence and Mortality Web-based Report. Atlanta:
U.S. Department of Health and Human Services, Centers for
Disease Control and Prevention and National Cancer Institute; 2017.
Available from:. www.cdc.gov/uscs (Accessed on: June 3, 2017).
[5]
Vang R, Shih Ie M, Kurman RJ. Ovarian low-grade and high-grade serous carcinoma: Pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol 2009; 16(5): 267-82.
[6]
Matz M, Coleman MP, Sant M, et al. The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2). Gynecol Oncol 2017; 144(2): 405-13.
[7]
Landen CN, Birrer MJ Jr, Sood AK. Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol 2008; 26(6): 995-1005.
[8]
Singh N, Gilks CB, Wilkinson N, McCluggage WG. The secondary Mullerian system, field effect, BRCA, and tubal fimbria: Our evolving understanding of the origin of tubo-ovarian high-grade serous carcinoma and why assignment of primary site matters. Pathology 2015; 47(5): 423-31.
[9]
Kindelberger DW, Lee Y, Miron A, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol 2007; 31(2): 161-9.
[10]
Gostout BS, Brewer MA. Guidelines for referral of the patient with an adnexal mass. Clin Obstet Gynecol 2006; 49(3): 448-58.
[11]
Thompson D, Easton DF. Breast cancer linkage consortium. Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002; 94(18): 1358-65.
[12]
American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Gynecology. Gynecologists’ committee on practice, practice bulletin no. 174: Evaluation and management of adnexal masses. Obstet Gynecol 2016; 128(5): e210-26.
[13]
Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: A combined analysis of 22 studies. Am J Hum Genet 2003; 72(5): 1117-30.
[14]
Titus-Ernstoff L, Perez K, Carmer DW, Harlow BL, Baron JA, Greenberg ER. Menstrual and reproductive factors in relation to ovarian cancer risk. Br J Cancer 2001; 84(5): 714-21.
[15]
Padilla LA, Radosevich DM, Milad MP. Limitations of the pelvic examination for evaluation of the female pelvic organs. Int J Gynaecol Obstet 2005; 88(1): 84-8.
[16]
Timmerman D, Van Calster B, Testa A, et al. Predicting the risk of malignancy in adnexal masses based on the simple rules from the International Ovarian Tumor Analysis group. Am J Obstet Gynecol 2016; 214(4): 424-37.
[17]
Geomini P, Kruitwagen R, Bremer GL, Cnossen J, Mol BW. The accuracy of risk scores in predicting ovarian malignancy: A systematic review. Obstet Gynecol 2009; 113(2 Pt 1): 384-94.
[18]
Guerriero S, Alcazar JL, Ajossa S, et al. Transvaginal color Doppler imaging in the detection of ovarian cancer in a large study population. Int J Gynecol Cancer 2010; 20(5): 781-6.
[19]
Glaser GE, Torres M, Kim B, et al. Preoperative clues to guide
primary approach in advanced ovarian cancer (OC): The role of CT
findings to predict the extent of tumor dissemination. J Clin Oncol 2011. 29(Suppl): abstr e15541).
[20]
Spencer JA, Ghattamaneni S. MR imaging of the sonographically indeterminate adnexal mass. Radiology 2010; 256(3): 677-94.
[21]
Thomassin-Naggara I, Bazot M, Daraï E, Callard P, Thomassin J, Cuenod CA. Epithelial ovarian tumors: Value of dynamic contrast-enhanced MR imaging and correlation with tumor angiogenesis. Radiology 2008; 248(1): 148-59.
[22]
Sohaib SA, Mills TD, Sahdev A, et al. The role of magnetic resonance imaging and ultrasound in patients with adnexal masses. Clin Radiol 2005; 60(3): 340-8.
[23]
Anthoulakis C, Nikoloudis N. Pelvic MRI as the “gold standard” in the subsequent evaluation of ultrasound-indeterminate adnexal lesions: A systematic review. Gynecol Oncol 2014; 132(3): 661-8.
[24]
Rockall AG, Cross A, Flanagan S, Moore E, Avril N. The role of FDG-PET/CT in gynaecological cancers. Cancer Imaging 2012; 12: 49-65.
[25]
Castellucci P, Perrone AM, Picchio M, et al. Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: correlation with transvaginal ultrasonography, computed tomography, and histology. Nucl Med Commun 2007; 28(8): 589-95.
[26]
Longoria TC, Ueland FR, Zhang Z, et al. Clinical performance of a multivariate index assay for detecting early-stage ovarian cancer. Am J Obstet Gynecol 2014; 210(1): 78.e1-9.
[27]
Sölétormos G, Duffy MJ, Othman Abu Hassan S, et al. Clinical use of cancer biomarkers in epithelial ovarian cancer: Updated guidelines from the european group on tumor markers. Int J Gynecol Cancer 2016; 26(1): 43-51.
[28]
Granato T, Porpora MG, Longo F, Angeloni A, Manganaro L, Anastasi E. HE4 in the differential diagnosis of ovarian masses. Clin Chim Acta 2015; 446: 147-55.
[29]
Ueland FR, Desimone CP, Seamon LG, et al. Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors. Obstet Gynecol 2011; 117(6): 1289-97.
[30]
Nowak M, Janas Ł, Stachowiak G, Stetkiewicz T, Wilczyński JR. Current clinical application of serum biomarkers to detect ovarian cancer. Przegl Menopauz 2015; 14(4): 254-9.
[31]
Eskander RN, Carpenter BA, Wu HG, Wolf JK. The clinical utility of an elevated-risk multivariate index assay score in ovarian cancer patients. Curr Med Res Opin 2016; 32(6): 1161-5.
[32]
Morgan RJ Jr, Alvarez RD, Armstrong DK, et al. Ovarian cancer, version 2.2013. J Natl Compr Canc Netw 2013; 11(10): 1199-209.
[33]
Moore RG, Miller MC, Disilvestro P, et al. Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass. Obstet Gynecol 2011; 118(2 Pt 1): 280-8.
[34]
Dayyani F, Uhlig S, Colson B, et al. Diagnostic performance of risk of ovarian malignancy algorithm against CA125 and HE4 in connection with ovarian cancer: A meta-analysis. Int J Gynecol Cancer 2016; 26(9): 1586-93.
[35]
Rauh-Hain JA, Melamed A, Buskwofie A, Schorge JO. Adnexal mass in the postmenopausal patient. Clin Obstet Gynecol 2015; 58(1): 53-65.
[36]
Fanfani F, Fagotti A, Ercoli A, et al. A prospective randomized study of laparoscopy and minilaparotomy in the management of benign adnexal masses. Hum Reprod 2004; 19(10): 2367-71.
[37]
Parker WH, Levine RL, Howard FM, Sansone B, Nerek JS. A multicenter study of laparoscopic management of selected cystic adnexal masses in postmenopausal women. J Am Coll Surg 1994; 179(6): 733-7.
[38]
Yuen PM, Yu KM, Yip SK, Lau WC, Rogers MS, Chang A. A randomized prospective study of laparoscopy and laparotomy in the management of benign ovarian masses. Am J Obstet Gynecol 1997; 177(1): 109-14.
Call for Papers in Thematic Issues
08 September, 2024
RARE CASES IN GYNECOLOGY-OBSTETRICS
With the development of diagnostic and therapeutic techniques (such as ART techniques) and the immersion of new pathologies (such as COVID19), we are witnessing an increase in the incidence of pathologies that were previously described as rare or exceptional. the practitioner sometimes confronts difficult situations in these cases in diagnostic ...read more
Article Metrics
12
2